Newsroom

News

June 24, 2022

The latest

argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe

Breda, the Netherlands

argenx today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended European Commission (EC) approval of efgartigimod as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

argenx Stories

See where we started — and where we’re going — as we chart a new course together in immunology.

Past Press Releases

June 1, 2022

argenx to Present at Upcoming Investor Conferences

May 31, 2022

argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis

May 19, 2022

argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases

May 10, 2022

argenx announces results of Annual General Meeting of Shareholders

Download assets

Get photos, fact sheets, illustrations and more.

Join the team

Dare to do more with a thriving career at Argenx.

Find your career

Follow us

Get the latest news and info via our social media channels.